Glow discharge plasma deposition (GDPD) technique for the local controlled delivery of hirudin from biomaterials

Pharmaceutical Research

Volumn 15, Issue 5, 1998, Pages 783-786

  Kim, Dae Duk ^a,b   Takeno, Marc M ^a   Ratner, Buddy D ^a   Horbett, Thomas A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Pusan National University   (South Korea)

Author keywords

Biomaterial; Electron spectroscopy for chemcal analysis (ESCA); Glow discharge plasma deposition (GDPD); Hirudin; Local drug delivery

Indexed keywords

BIOMATERIAL; BIOSPAN; HIRUDIN; POLYURETHAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD COMPATIBILITY; CONTROLLED DRUG RELEASE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; LEECH; MOLECULAR WEIGHT; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SPECTROSCOPY; THROMBOGENICITY;

ANTITHROMBINS; BIOCOMPATIBLE MATERIALS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HIRUDINS; METHACRYLATES; MICROSCOPY, ELECTRON, SCANNING;

EID: 0031750539     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011987423502     Document Type: Article

References (14)

1. F. Markwardt. Past, present and future of hirudin. Haemost. 21(suppl 1): 11-26 (1991).
2. R. J. Levy, V. Labhasetwar, C. Song, E. Lerner, W. Chen, N. Vyavahare, and X. Qu. Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis. J. Control. Rel. 36:137-147 (1995).
3. D. D. Kim, T. A. Horbett, M. M. Takeno, and B. D. Ranter.Pharmacology and controlled release of hirudin for cardiovascular disorders. Cardiovas. Pathol. 5:337-349 (1996).
4. G. P. Lopez, B. D. Ratner, C. D. Tidwell, C. L. Haycox, R. J. Rapoza, and T. A. Horbett. Glow discharge plasma deposition of tetraethylene glycol dimethyl ether for fouling-resistant biomaterial surfaces. J. Biomed. Mater. Res. 26: 415-439 (1992).
5. M. M. Takeno, T. A. Horbett, and B. D. Ratner. A novel matrix for the controlled release of the anti-thrombotic peptide, echistatin, Proc. Intern. Symp. Control. Rel. Bioact. Mater. 22:147 (1995).
6. Y. Haque and B. D. Ratner. Preparation and properties of plasma deposited films with surface energies varying over a wide range. J. Appl. Polym. Sci. 32: 4369-4381 (1986).
7. M. Spannagl, H. Bichler, H. Lill, and W. Shramm. A fast photometric assay for the determination of hirudin. Haemost. 21(supple 1):36-40 (1991).
8. B. D. Ratner, A. Chilkoti, and G. P. Lopez. Plasma deposition and treatment for biomedical application. In: Plasma deposition, treatment and etching of polymers. R. D'Agostino (ed.), Academic Press, San Diego, 1990, pp. 463-516.
9. W. D. Rhine, D. S. T. Hsieh, and R. Langer. Polymers for sustained macromolecule release: Procedures to fabricate reproducible delivery systems and control release kinetics. J. Pharm. Sci. 69:265-270 (1980).
10. M. N. Ali, V. Levy, and A. I. Schafer. The role of thrombin and thrombin inhibitors in coronary angioplasty. Chest 108:1409-1419 (1995).
11. R. Riessen and J. M. Isner. Prospects for site-specific delivery of pharmacologic and molecular therapies. J. Am. Coll. Cardiol. 23: 1234-1244 (1994).
12. R. J. Levy. Pharmaceutic stents and regional therapy for restenosis. In E. J. Topol (2nd eds.), Textbook of Interventional Cardiology, Saunders, Philadelphia, 1992, pp. 776-786.
13. J. Fareed, J. M. Walenga, D. Hoppensteadt, L. Lyer, and R. Pifarre. Neutralization of recombinant hirudin: Some practical considerations. Semin. Thromb. Hemost. 17: 137-144 (1991).
14. F. Markwardt. Past, present and future of hirudin. Haemost. 21(suppl 1): 11-26 (1991).